Zydus Lifesciences reports strong Q3 & 9M FY26 growth
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The revenues this quarter are in line with the outlook we envisaged for the year
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
Subscribe To Our Newsletter & Stay Updated